C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function

Journal of Cardiovascular Medicine

Volumn 9, Issue 6, 2008, Pages 581-588

  Lombardi, Federico ^a   Tundo, Fabrizio ^a   Belletti, Sebastiano ^a   Mantero, Antonio ^a   Melzi D'Eril, Gian Vico ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atrial fibrillation; Electrical cardioversion; Natriuretic peptide; Structural remodeling; Subclinical inflammation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CARDIOVERSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; PREDICTION; PROTEIN BLOOD LEVEL; RECURRENCE RISK; SINUS RHYTHM;

AGED; ATRIAL FIBRILLATION; ATRIAL FUNCTION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECURRENCE; STROKE VOLUME;

EID: 43549110070     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282f3524d     Document Type: Article

References (30)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-1022.
2. Tieleman RG, Van Gelder IC, Crijns HJ, De Kam PJ, Van Den Berg MP, Haaksma J, et al. Early recurrence of atrial fibrillation after electrical cardioversion: a result of fibrillation induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31:167-173.
3. Lafuente-Lafuente C, Mouly S, Longàs-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation. Arch Intern Med 2006; 166:719-728.
4. Allessie MA, Konings K, Kirchhof C, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996;77:10A-23A.
5. Allessie MA, Boyden PA, Camm JA, Kleber AG, Lab MJ, Legato MJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001;103:769-777.
6. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083-2092.
7. Boos JB, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27:137-149.
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
9. Antonielli E, Pizzuti A, Palinkas A, Tanga M, Gruber N, Michelassi C, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2002; 39:1443-1449.
10. Mark DB, Felker GM. B-type natriuretic peptide: a biomarker for all seasons? N Engl J Med 2004; 350:718-720.
11. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322.
12. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
13. Wozawkoska-Kaplon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol 2004;93:1555-1558.
14. Buob A, Jung J, Siaplaouras S, Neuberger H-R, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. PACE 2006; 29:559-563.
15. Mathew JP, Fontes ML, Tudor JC, Ramsey J, Duke P, Mazer CD, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. J Am Med Assoc 2004; 291:1720-1729.
16. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrates of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-1184.
17. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95:764-767.
18. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammation-related pathways. Lab Invest 2002; 82:747-756.
19. Malouf JF, Kanagola R, AlAtawi FO, Rosales AG, Davison DE, Murali NS, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005;46:1284-1287.
20. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108:346-353.
21. Wazni O, Martin DO, Marrouche NF, Shaaraoui M, Chung MK, Almahameed S, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005; 91:1303-1305.
22. Zarauza J, Rodriguez Lera MJ, Farinas Alvarez C, Hernando JP, Ceballos B, Gutierrez B, et al. Relationship between C-reactive protein level and early recurrence of atrial fibrillation after electrical cardioversion. Rev Esp Cardiol 2006; 59:125-129.
23. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-reactive protein in lone atrial fibrillation. Am J Cardiol 2006; 97:1346-1350.
24. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidid A, Stakos D, Floros D, Papanas N, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006; 97:659-661.
25. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94:805-807.
26. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832-1839.
27. Boos CJ, Lip GYH. Prevention of atrial fibrillation by angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: some pathophysiological insights. J Am Coll Cardiol 2006; 47:889-890.
28. Ozaydin M, Varol E, Aslam SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97:1490-1493.
29. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25:1100-1107.
30. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized controlled trial. J Am Coll Cardiol 2005;45:1723-1728.